[go: up one dir, main page]

FR22C1047I1 - Derives de benzimidazole-proline - Google Patents

Derives de benzimidazole-proline

Info

Publication number
FR22C1047I1
FR22C1047I1 FR22C1047C FR22C1047C FR22C1047I1 FR 22C1047 I1 FR22C1047 I1 FR 22C1047I1 FR 22C1047 C FR22C1047 C FR 22C1047C FR 22C1047 C FR22C1047 C FR 22C1047C FR 22C1047 I1 FR22C1047 I1 FR 22C1047I1
Authority
FR
France
Prior art keywords
benzimidazole
proline derivatives
proline
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1047C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of FR22C1047I1 publication Critical patent/FR22C1047I1/fr
Application granted granted Critical
Publication of FR22C1047I2 publication Critical patent/FR22C1047I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR22C1047C 2012-06-04 2022-09-13 Derives de benzimidazole-proline Active FR22C1047I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12170748 2012-06-04
EP13158520 2013-03-11
PCT/IB2013/054567 WO2013182972A1 (fr) 2012-06-04 2013-06-03 Dérivés de benzimidazole-proline
EP13744805.6A EP2855453B1 (fr) 2012-06-04 2013-06-03 Dérivés de benzimidazole-proline

Publications (2)

Publication Number Publication Date
FR22C1047I1 true FR22C1047I1 (fr) 2022-10-14
FR22C1047I2 FR22C1047I2 (fr) 2023-08-18

Family

ID=48914370

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1047C Active FR22C1047I2 (fr) 2012-06-04 2022-09-13 Derives de benzimidazole-proline

Country Status (33)

Country Link
US (3) US9732075B2 (fr)
EP (1) EP2855453B1 (fr)
JP (1) JP5814491B2 (fr)
KR (3) KR101689093B1 (fr)
CN (1) CN104334544B (fr)
AR (1) AR091257A1 (fr)
AU (1) AU2013273222B2 (fr)
BR (1) BR112014030173B1 (fr)
CA (1) CA2873341C (fr)
CL (1) CL2014003294A1 (fr)
CY (2) CY1118735T1 (fr)
DK (1) DK2855453T3 (fr)
EA (2) EA029899B1 (fr)
ES (1) ES2617863T3 (fr)
FR (1) FR22C1047I2 (fr)
HK (1) HK1208449A1 (fr)
HR (1) HRP20170351T1 (fr)
HU (2) HUE031753T2 (fr)
IL (1) IL236024A (fr)
LT (2) LT2855453T (fr)
MX (1) MX354102B (fr)
MY (1) MY169986A (fr)
NL (1) NL301197I2 (fr)
NO (1) NO2022044I1 (fr)
NZ (1) NZ703448A (fr)
PH (1) PH12014502540B1 (fr)
PL (1) PL2855453T3 (fr)
PT (1) PT2855453T (fr)
SG (2) SG11201408004SA (fr)
SI (1) SI2855453T1 (fr)
TW (2) TWI510481B (fr)
WO (1) WO2013182972A1 (fr)
ZA (1) ZA201409422B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807000C (fr) 2010-08-24 2018-12-04 Actelion Pharmaceuticals Ltd Derives de proline sulfonamide comme antagonistes des recepteurs de l'orexine
EA029899B1 (ru) 2012-06-04 2018-05-31 Идорсиа Фармасьютиклз Лтд Производные бензимидазол-пролина
SG11201502493XA (en) 2012-10-10 2015-04-29 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
WO2014141065A1 (fr) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Dérivés d'amide d'azétidine en tant qu'antagonistes des récepteurs d'oréxine
TR201807959T4 (tr) 2013-07-22 2018-06-21 Idorsia Pharmaceuticals Ltd 1-(Piperazın-1-il)-2- ([1,2,4] triazol-1-il)-etanon türevleri.
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
NO3077389T3 (fr) * 2013-12-03 2018-02-10
EP3077391B1 (fr) * 2013-12-04 2018-08-15 Idorsia Pharmaceuticals Ltd Utilisation de dérivés de benzimidazole-proline
SG11201606839SA (en) * 2014-02-20 2016-09-29 Takeda Pharmaceutical Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
TW201613864A (en) * 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
CN107250133B (zh) * 2015-01-15 2020-09-15 爱杜西亚药品有限公司 作为cxcr3受体调节剂的羟烷基哌嗪衍生物
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
WO2017012502A1 (fr) 2015-07-17 2017-01-26 Sunshine Lake Pharma Co., Ltd. Composés de quinazoline substitués, ainsi que préparation et utilisations de ceux-ci
DK3355890T3 (da) 2015-10-01 2022-01-03 Biocryst Pharm Inc Humane plasmakallikreininhibitorer
US10370380B2 (en) 2015-11-23 2019-08-06 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
HUE055904T2 (hu) 2017-05-03 2021-12-28 Idorsia Pharmaceuticals Ltd 2-([1,2,3]triazol-2-il)-benzoesav-származékok elõállítása
WO2019002344A1 (fr) 2017-06-29 2019-01-03 Lonza Guangzhou Nansha Ltd. Procédé de préparation d'alpha-méthyl-l-proline
WO2020007964A1 (fr) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd Dérivés de 2-(2-azabicyclo [3.1.0] hexan-1-yl)-1h-benzimidazole
WO2020007977A1 (fr) 2018-07-06 2020-01-09 Idorsia Pharmaceuticals Ltd Dérivés de 7-trifluorométhyl-[1,4]diazépane
CN108997308A (zh) * 2018-07-09 2018-12-14 西藏大学 一种苯并咪唑类衍生物及其制备方法和应用
WO2020099511A1 (fr) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Dérivés de benzimidazole-2-méthyl-morpholine
JP2023521492A (ja) 2020-04-19 2023-05-24 イドーシア ファーマシューティカルズ リミテッド ダリドレキサントの医学的用途
BR112023015463A2 (pt) * 2021-02-02 2023-10-10 Medshine Discovery Inc Composto tetrahidropirrolocíclico e aplicação do mesmo
CN115925699B (zh) * 2022-02-25 2023-10-03 南京知和医药科技有限公司 具有镇痛活性的稠环化合物及其制备方法与用途
WO2023218023A1 (fr) 2022-05-13 2023-11-16 Idorsia Pharmaceuticals Ltd Dérives d'hydrazine-n-carboxamide cycliques substitués par thiazoloaryl-méthyle
CN116239575A (zh) * 2023-03-13 2023-06-09 南开大学 一种新型联萘咪唑啉三齿手性配体的制法及其应用
CN118724879B (zh) * 2023-12-19 2025-02-11 南京知和医药科技有限公司 一种氘代稠环化合物及其制备方法与用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282927A (en) 1964-05-21 1966-11-01 Bristol Myers Co 5-phenyl-4-thiazolylpenicillins
AUPQ253199A0 (en) 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist
US6677354B2 (en) 2000-06-16 2004-01-13 Smithkline Beecham P.L.C. Piperdines for use as orexin receptor antagonists
KR20030060904A (ko) 2000-10-06 2003-07-16 뉴로젠 코포레이션 Ｃｒｆ 수용체 조절자로서 벤즈이미다졸 및 인돌 유도체
ATE286897T1 (de) 2000-11-28 2005-01-15 Smithkline Beecham Plc Morpholinderivate als antagonisten an orexinrezeptoren
EP1435955A2 (fr) 2001-05-05 2004-07-14 SmithKline Beecham P.L.C. Derives d'amines cycliques n-aroyl utilises comme antagonistes du recepteur d'orexine
CA2446396A1 (fr) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. Amines cycliques n-aroyle
WO2003002561A1 (fr) * 2001-06-28 2003-01-09 Smithkline Beecham P.L.C. Derives d'amine cycliques n-aroyle utilises comme antagonistes du recepteur de l'orexine
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
DE10240818A1 (de) 2002-08-30 2004-05-13 Grünenthal GmbH Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
WO2004026866A1 (fr) 2002-09-18 2004-04-01 Glaxo Group Limited Amines cycliques n-aroyle utilisees comme antagonistes du recepteur d'orexine
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
AR044586A1 (es) 2003-06-04 2005-09-21 Aventis Pharma Sa Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7763638B2 (en) 2004-03-01 2010-07-27 Actelion Pharmaceuticals Ltd. Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
US20050272784A1 (en) 2004-05-07 2005-12-08 Xiaobing Li Inhibitors of bacterial Type III protein secretion systems
EP1604989A1 (fr) 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft Inhibiteurs de DPP-IV
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
GB0510142D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
HUP0500920A2 (en) 2005-10-05 2007-07-30 Richter Gedeon Nyrt Oxadiazole derivatives, process for their preparation and their use
CA2644010A1 (fr) 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Derives de tetrahydroisoquinoleine pour renforcer la fonction de la memoire
AU2007272854B2 (en) 2006-07-14 2013-08-01 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
CA2659299A1 (fr) 2006-08-15 2008-02-21 Actelion Pharmaceuticals Ltd Composes d'azetidine
TW200823227A (en) 2006-09-29 2008-06-01 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
US8124623B2 (en) 2006-11-10 2012-02-28 Actelion Pharmaceuticals Ltd. 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
TW200833328A (en) 2006-12-28 2008-08-16 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives
WO2008087611A2 (fr) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Dérivés de pyrrolidine et de piperidine
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
JP2010526869A (ja) 2007-05-14 2010-08-05 アクテリオン ファーマシューティカルズ リミテッド ２−シクロプロピル−チアゾール誘導体
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8030495B2 (en) 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
PE20090441A1 (es) 2007-07-03 2009-05-08 Glaxo Group Ltd DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
US8106215B2 (en) 2007-07-03 2012-01-31 Actelion Pharmaceuticals Ltd. 3-aza-bicyclo[3.3.0]octane compounds
WO2009004772A1 (fr) 2007-07-05 2009-01-08 Panasonic Corporation Dispositif de commande de bras de robot et procédé de commande, robot et programme de commande
AR067665A1 (es) 2007-07-27 2009-10-21 Actelion Pharmaceuticals Ltd Derivados de trans-3- aza-biciclo ( 3.1.0) hexano
NZ583487A (en) 2007-07-27 2011-09-30 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.3.0]octane derivatives
EP2185512B1 (fr) 2007-07-27 2010-12-29 Actelion Pharmaceuticals Ltd. Dérivés de trans-3-aza-bicyclo[3.1.0]hexane
JP2010540429A (ja) 2007-09-24 2010-12-24 アクテリオン ファーマシューティカルズ リミテッド オレキシン受容体拮抗薬としてのピロリジン類及びピペリジン類
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
CN101903378B (zh) 2007-12-18 2014-03-12 埃科特莱茵药品有限公司 氨基三唑衍生物
RU2010138640A (ru) * 2008-02-21 2012-03-27 Актелион Фармасьютиклз Лтд (Ch) Производные 2-аза-бицикло [2.2.1] гептана
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
CN102083827A (zh) 2008-07-07 2011-06-01 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的噻唑烷化合物
WO2010038200A1 (fr) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Composés d'oxazolidine utilisables en tant qu'antagonistes des récepteurs à orexine
BRPI0920183A2 (pt) 2008-10-14 2018-05-22 Actelion Pharmaceuticals Ltd derivados de fenetilamida e seus analogos heterociclicos
WO2010048012A1 (fr) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. Antagonistes de récepteur d’orexine de pipéridine 2,5-disubstituée
JP2012509912A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
EP2358712A1 (fr) 2008-11-26 2011-08-24 Glaxo Group Limited Dérivés de la pipéridine utiles en tant qu antagonistes du récepteur de l orexine
WO2010060470A1 (fr) 2008-11-26 2010-06-03 Glaxo Group Limited Dérivés de la pipéridine utiles en tant qu’antagonistes du récepteur de l’orexine
US8133908B2 (en) 2008-12-02 2012-03-13 Glaxo Group Limited Heteroaryl derivatives of N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-amine
MX2011005800A (es) 2008-12-02 2011-06-20 Glaxo Group Ltd Derivados de n{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4. 1.0]hept-4-il]metil}-2-heteroarilamina y sus usos.
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
AU2010232628A1 (en) 2009-04-03 2011-10-06 Merck Canada Inc. Renin inhibitors
WO2010122151A1 (fr) 2009-04-24 2010-10-28 Glaxo Group Limited 3 -azabicyclo [4.1.0] heptanes utilisés comme antagonistes de l'orexine
JP5095035B2 (ja) 2009-06-09 2012-12-12 アクテリオン ファーマシューティカルズ リミテッド フッ素化アミノトリアゾール誘導体
KR20120105449A (ko) 2009-10-23 2012-09-25 얀센 파마슈티카 엔.브이. 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로［3,4-ｃ］피롤
EP2491031B1 (fr) 2009-10-23 2013-08-07 Janssen Pharmaceutica N.V. Composés hétérocycliques condensés en tant que modulateurs de récepteur d'orexine
WO2011050200A1 (fr) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Composés hétérocycliques condensés en tant que modulateurs de récepteur d'orexine
AU2011207679B2 (en) 2010-01-19 2013-10-10 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
CA2807000C (fr) 2010-08-24 2018-12-04 Actelion Pharmaceuticals Ltd Derives de proline sulfonamide comme antagonistes des recepteurs de l'orexine
MX2013002927A (es) 2010-09-24 2013-05-30 Bristol Myers Squibb Co Inhibidores del virus de la hepatitis c.
EP2638008B1 (fr) 2010-11-10 2015-07-01 Actelion Pharmaceuticals Ltd Dérivés de lactame utiles en tant qu'antagonistes du récepteur de l'orexine
EP2675801B1 (fr) 2011-02-18 2015-04-08 Actelion Pharmaceuticals Ltd. Nouveaux dérivés de pyrazole et d'imidazole utiles à titre d'antagonistes d'orexine
KR101676930B1 (ko) 2011-11-08 2016-11-16 액테리온 파마슈티칼 리미티드 오렉신 수용체 길항제로서의 ２-(１,２,３-트리아졸-２-일)벤즈아미드 및 ３-(１,２,３-트리아졸-２-일)피콜린아미드 유도체
EA029899B1 (ru) 2012-06-04 2018-05-31 Идорсиа Фармасьютиклз Лтд Производные бензимидазол-пролина
SG11201502493XA (en) 2012-10-10 2015-04-29 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
WO2014141065A1 (fr) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Dérivés d'amide d'azétidine en tant qu'antagonistes des récepteurs d'oréxine
NO3077389T3 (fr) 2013-12-03 2018-02-10
UA119151C2 (uk) * 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
EP3077391B1 (fr) 2013-12-04 2018-08-15 Idorsia Pharmaceuticals Ltd Utilisation de dérivés de benzimidazole-proline

Also Published As

Publication number Publication date
ZA201409422B (en) 2021-05-26
PT2855453T (pt) 2017-03-09
US20150166527A1 (en) 2015-06-18
HRP20170351T1 (hr) 2017-04-21
LTPA2022518I1 (fr) 2022-09-26
WO2013182972A1 (fr) 2013-12-12
TW201400476A (zh) 2014-01-01
NO2022044I1 (no) 2022-10-27
AR091257A1 (es) 2015-01-21
CA2873341A1 (fr) 2013-12-12
SG11201408004SA (en) 2015-01-29
BR112014030173B1 (pt) 2022-10-04
EA201600366A1 (ru) 2016-08-31
CN104334544A (zh) 2015-02-04
AU2013273222A1 (en) 2015-01-29
PH12014502540A1 (en) 2015-01-21
IL236024A0 (en) 2015-02-01
KR20180115804A (ko) 2018-10-23
TWI510481B (zh) 2015-12-01
US11040966B2 (en) 2021-06-22
JP2015522558A (ja) 2015-08-06
US10329287B2 (en) 2019-06-25
MX354102B (es) 2018-02-13
MY169986A (en) 2019-06-19
NZ703448A (en) 2017-07-28
CL2014003294A1 (es) 2015-03-20
SI2855453T1 (sl) 2017-05-31
KR20160088439A (ko) 2016-07-25
EA029899B1 (ru) 2018-05-31
MX2014014885A (es) 2015-03-05
JP5814491B2 (ja) 2015-11-17
LT2855453T (lt) 2017-02-27
TWI570120B (zh) 2017-02-11
HUE031753T2 (en) 2017-07-28
CA2873341C (fr) 2018-01-02
DK2855453T3 (en) 2017-02-06
EP2855453A1 (fr) 2015-04-08
CY1118735T1 (el) 2017-07-12
EA028046B1 (ru) 2017-10-31
CN104334544B (zh) 2016-10-19
AU2013273222B2 (en) 2017-11-02
SG10201702540UA (en) 2017-05-30
US20170305897A1 (en) 2017-10-26
HK1208449A1 (en) 2016-03-04
CY2022027I1 (el) 2023-01-05
TW201600517A (zh) 2016-01-01
KR101946128B1 (ko) 2019-02-08
PH12014502540B1 (en) 2015-01-21
PL2855453T3 (pl) 2017-05-31
US20190263797A1 (en) 2019-08-29
ES2617863T3 (es) 2017-06-20
EP2855453B1 (fr) 2016-12-07
NL301197I2 (nl) 2022-11-04
EA201401351A1 (ru) 2015-05-29
FR22C1047I2 (fr) 2023-08-18
BR112014030173A8 (pt) 2017-12-26
US9732075B2 (en) 2017-08-15
KR101689093B1 (ko) 2016-12-22
NL301197I1 (fr) 2022-10-05
KR101995683B1 (ko) 2019-07-02
KR20150023640A (ko) 2015-03-05
HUS2200040I1 (hu) 2022-09-28
CY2022027I2 (el) 2023-01-05
IL236024A (en) 2016-09-29
BR112014030173A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
FR22C1047I2 (fr) Derives de benzimidazole-proline
SMT201700065B (it) Derivato piridonico
DK2859055T3 (da) Polymercoatings
DK2825087T3 (da) Otoscanner
EP2838490A4 (fr) Système de fixation de tube
EP2809145A4 (fr) Peptides de transit des chloroplastes
DK2839013T3 (da) Ikke-disruptiv-gen-targetering
EP2814472A4 (fr) Agents réducteurs dithioamine
EP2805877A4 (fr) Sous-nappe
DK2873977T3 (da) Dobbeltdækker-rørdispenser
CO6990736A2 (es) Pirrolidina-2-carboxamidas sustituídas
DE112012006109A5 (de) Okklusionsschienenanordnung
DK2854722T3 (da) Stomipose
PT2944633T (pt) Derivado de piridina
AR092198A1 (es) Derivados de pirazolopirimidinas
EP2941099A4 (fr) Dispositif de commutation
EP2831482A4 (fr) Joint de rebord
CO7020919A2 (es) Derivados de tetrahidro-quinazolinona
EP2862861A4 (fr) Dérivé de pipéridinylpyrazolopyridine
EP2899849A4 (fr) Structure de fixation de stator
DK2825157T3 (da) Aminosyrelipider
EP2812047A4 (fr) Système d'accès via une occlusion
CO6960557A2 (es) Derivados de 2-yodo-imidazol
EP2869113A4 (fr) Dispositif d'affichage pour véhicule
DK2831122T3 (da) Anthocyanidin-kompleks